Literature DB >> 28169928

Prognostic Significance of Postoperative Complications After Curative Resection for Patients With Esophageal Squamous Cell Carcinoma.

Hiroshi Saeki1, Satoshi Tsutsumi, Hirotada Tajiri, Takafumi Yukaya, Ryosuke Tsutsumi, Sho Nishimura, Yu Nakaji, Kensuke Kudou, Shingo Akiyama, Yuta Kasagi, Ryota Nakanishi, Yuichiro Nakashima, Masahiko Sugiyama, Kippei Ohgaki, Hideto Sonoda, Eiji Oki, Yoshihiko Maehara.   

Abstract

OBJECTIVE: The objective of this study was to elucidate the impact of postoperative complications on long-term survival after curative resection for esophageal squamous cell carcinoma.
BACKGROUND: The relation between postoperative complications and long-term survival after curative surgery for esophageal squamous cell carcinoma is controversial; thus, this issue should be resolved with a large-scale, well-designed study.
METHODS: Clinicopathological features and survival of 580 consecutive patients who received curative resection for esophageal squamous cell carcinoma were investigated according to the development of postoperative pulmonary complications and anastomotic leakage.
RESULTS: The 5-year survival rates of patients with pStage 0, I, and II disease with postoperative complications (n = 116) were significantly poorer than those of patients without postoperative complications (n = 288) (overall 69.6% vs 46.9%, P < 0.0001; disease-specific; 76.7% vs 58.9%, P < 0.0022), whereas no differences were found in patients with pStage III and IV disease (n = 176). In the univariate and multivariate analyses for disease-specific survival, pT3, pT4, pN positivity, and development of postoperative complications were significant prognostic factors in all patients. Also, when the analysis was limited to the pStage 0, I, and II patients, development of postoperative complications, and pT3, pT4, and pN positivity, were found to be independent poor prognostic factors in multivariate analyses (hazard ratio: 1.56, 95% confidence interval, 1.01-2.41, P = 0.0476).
CONCLUSIONS: The development of postoperative complications is an independent disease-specific poor prognostic factor after curative resection for patients with less-advanced esophageal squamous cell carcinoma.

Entities:  

Mesh:

Year:  2017        PMID: 28169928     DOI: 10.1097/SLA.0000000000001692

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  29 in total

1.  Comparison of perioperative and oncological outcome of thoracoscopic esophagectomy in left decubitus position and in prone position for esophageal cancer.

Authors:  Shirou Kuwabara; Kazuaki Kobayashi; Akira Kubota; Ikuma Shioi; Kenji Yamaguchi; Norio Katayanagi
Journal:  Langenbecks Arch Surg       Date:  2018-04-15       Impact factor: 3.445

Review 2.  Recent progress in perioperative management of patients undergoing esophagectomy for esophageal cancer.

Authors:  Masayuki Watanabe; Akihiko Okamura; Tasuku Toihata; Kotaro Yamashita; Masami Yuda; Masaru Hayami; Ian Fukudome; Yu Imamura; Shinji Mine
Journal:  Esophagus       Date:  2018-04-25       Impact factor: 4.230

3.  Clinical usefulness of the surgical Apgar score for estimating short-term and prognostic outcomes after esophagectomy.

Authors:  Naoya Yoshida; Hideo Baba
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

4.  Risk factors for pulmonary morbidities after minimally invasive esophagectomy for esophageal cancer.

Authors:  Tomoyuki Uchihara; Naoya Yoshida; Yoshifumi Baba; Taisuke Yagi; Tasuku Toihata; Eri Oda; Daisuke Kuroda; Tsugio Eto; Mayuko Ohuchi; Kenichi Nakamura; Hiroshi Sawayama; Koichi Kinoshita; Masaaki Iwatsuki; Takatsugu Ishimoto; Yasuo Sakamoto; Hideo Baba
Journal:  Surg Endosc       Date:  2017-12-22       Impact factor: 4.584

5.  Inflammatory response and recurrence after minimally invasive esophagectomy.

Authors:  Akihiko Okamura; Kotaro Yamashita; Ryotaro Kozuki; Keita Takahashi; Tasuku Toihata; Yu Imamura; Shinji Mine; Masayuki Watanabe
Journal:  Langenbecks Arch Surg       Date:  2019-08-30       Impact factor: 3.445

6.  Intra-Abdominal Complications after Curative Gastrectomies Worsen Prognoses of Patients with Stage II-III Gastric Cancer.

Authors:  Kader A T M Abdul; Yuki Murakami; Miwa Yoshimoto; Kazunari Onishi; Hirohiko Kuroda; Tomoyuki Matsunaga; Yoji Fukumoto; Shuichi Takano; Naruo Tokuyasu; Tomohiro Osaki; Hiroaki Saito; Masahide Ikeguchi
Journal:  Yonago Acta Med       Date:  2016-09-12       Impact factor: 1.641

7.  The prognostic significance of the comprehensive complication index in patients with gastric cancer.

Authors:  Shota Shimizu; Hiroaki Saito; Yusuke Kono; Yuki Murakami; Yuji Shishido; Kozo Miyatani; Tomoyuki Matsunaga; Yoji Fukumoto; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2019-05-30       Impact factor: 2.549

8.  Preoperative Smoking Cessation is Integral to the Prevention of Postoperative Morbidities in Minimally Invasive Esophagectomy.

Authors:  Naoya Yoshida; Kenichi Nakamura; Daisuke Kuroda; Yoshifumi Baba; Yuji Miyamoto; Masaaki Iwatsuki; Yukiharu Hiyoshi; Takatsugu Ishimoto; Yu Imamura; Masayuki Watanabe; Hideo Baba
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

Review 9.  The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms.

Authors:  Kosuke Mima; Shuji Ogino; Shigeki Nakagawa; Hiroshi Sawayama; Koichi Kinoshita; Ryuichi Krashima; Takatsugu Ishimoto; Katsunori Imai; Masaaki Iwatsuki; Daisuke Hashimoto; Yoshifumi Baba; Yasuo Sakamoto; Yo-Ichi Yamashita; Naoya Yoshida; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  Surg Oncol       Date:  2017-07-21       Impact factor: 3.279

10.  The survival impact of postoperative complications after curative resection in patients with esophageal squamous cell carcinoma: propensity score-matching analysis.

Authors:  Manabu Yamamoto; Mototsugu Shimokawa; Daisuke Yoshida; Shohei Yamaguchi; Mitsuhiko Ohta; Akinori Egashira; Masahiko Ikebe; Masaru Morita; Yasushi Toh
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-17       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.